WO2002014536A3 - Procedes permettant de moduler des proteines kinase a lignee multiple et de cribler des composes les modulant - Google Patents

Procedes permettant de moduler des proteines kinase a lignee multiple et de cribler des composes les modulant Download PDF

Info

Publication number
WO2002014536A3
WO2002014536A3 PCT/US2001/024822 US0124822W WO0214536A3 WO 2002014536 A3 WO2002014536 A3 WO 2002014536A3 US 0124822 W US0124822 W US 0124822W WO 0214536 A3 WO0214536 A3 WO 0214536A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein
methods
compound
linease
odulating
Prior art date
Application number
PCT/US2001/024822
Other languages
English (en)
Other versions
WO2002014536A9 (fr
WO2002014536A2 (fr
Inventor
Anna Maroney
Kevin M Walton
Craig A Dionne
Nicola Neff
Ernest Knight Jr
Marcie A Glicksman
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR0113266-0A priority Critical patent/BR0113266A/pt
Priority to SK269-2003A priority patent/SK2692003A3/sk
Application filed by Cephalon Inc filed Critical Cephalon Inc
Priority to AU2001283179A priority patent/AU2001283179B2/en
Priority to HU0501110A priority patent/HUP0501110A3/hu
Priority to JP2002519661A priority patent/JP2005503102A/ja
Priority to EP01961958A priority patent/EP1309721A2/fr
Priority to IL15431101A priority patent/IL154311A0/xx
Priority to NZ524034A priority patent/NZ524034A/en
Priority to AU8317901A priority patent/AU8317901A/xx
Priority to CA002419985A priority patent/CA2419985A1/fr
Priority to MXPA03001218A priority patent/MXPA03001218A/es
Publication of WO2002014536A2 publication Critical patent/WO2002014536A2/fr
Publication of WO2002014536A3 publication Critical patent/WO2002014536A3/fr
Priority to NO20030658A priority patent/NO20030658L/no
Priority to IS6711A priority patent/IS6711A/is
Priority to HR20030162A priority patent/HRP20030162A2/hr
Priority to BG107623A priority patent/BG107623A/bg
Publication of WO2002014536A9 publication Critical patent/WO2002014536A9/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)

Abstract

Cette invention a trait à des procédés permettant d'identifier des composés qui modulent l'activité d'une protéine kinase à lignée multiple et favorisent la survie ou la mort de cellules. Ces procédés consistent à mettre en contact la cellule contenant cette protéine avec le composé, à déterminer si ce composé diminue l'activité de celle-ci et s'il favorise la survie des cellules. L'invention concerne également des procédés permettant d'identifier des composés susceptibles d'être utilisés dans le traitement de troubles neurodégénératifs et/ou inflammatoires. Elle porte, en outre, sur des procédés visant à moduler l'activité de cette protéine, lesquels procédés consistent à mettre en contact la protéine ou la cellule contenant la protéine avec un composé indéno ou indolo. Elle concerne également des méthodes de traitement de troubles neurodégénératifs et/ou inflammatoires.
PCT/US2001/024822 2000-08-11 2001-08-08 Procedes permettant de moduler des proteines kinase a lignee multiple et de cribler des composes les modulant WO2002014536A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL15431101A IL154311A0 (en) 2000-08-11 2001-08-08 Modulating multiple lineage kinase proteins
NZ524034A NZ524034A (en) 2000-08-11 2001-08-08 Methods for modulating multiple lineage kinase proteins and screening compounds which modulate multiple linease kinase proteins
AU2001283179A AU2001283179B2 (en) 2000-08-11 2001-08-08 Modulating multiple lineage kinase proteins
HU0501110A HUP0501110A3 (en) 2000-08-11 2001-08-08 Odulating multiple lineage kinase proteins
JP2002519661A JP2005503102A (ja) 2000-08-11 2001-08-08 多重系統キナーゼタンパク質の調節および多重系統キナーゼタンパク質を調節する化合物のスクリーニング方法。
EP01961958A EP1309721A2 (fr) 2000-08-11 2001-08-08 Modulattion des proteines kinase a lignee multiple
SK269-2003A SK2692003A3 (en) 2000-08-11 2001-08-08 Methods of modulation of the multiple lineage kinase proteins and screening of compounds that modulate multiple lineage kinase proteins
BR0113266-0A BR0113266A (pt) 2000-08-11 2001-08-08 Métodos para modular proteìnas quinase de linhagem múltipla e compostos protetores que modulam proteìnas quinase de linhagem múltipla
AU8317901A AU8317901A (en) 2000-08-11 2001-08-08 Methods for modulating multiple lineage kinase proteins and screening compounds which modulate multiple linease kinase proteins
MXPA03001218A MXPA03001218A (es) 2000-08-11 2001-08-08 Metodos para modular proteinas kinasa de linaje multiple y para estudiar compuestos que modulan proteinas kinasa de linaje multiple.
CA002419985A CA2419985A1 (fr) 2000-08-11 2001-08-08 Procedes permettant de moduler des proteines kinase a lignee multiple et de cribler des composes les modulant
IS6711A IS6711A (is) 2000-08-11 2003-02-10 Mótun fjölætta kínasa próteina
NO20030658A NO20030658L (no) 2000-08-11 2003-02-10 Fremgangsmåte for modulering av multippel ''lineage'' kinaseproteiner og undersökelse av forbindelser som modulerer multippel "lineage"kinaseproteiner
HR20030162A HRP20030162A2 (en) 2000-08-11 2003-03-06 Modulating multiple lineage kinase proteins
BG107623A BG107623A (bg) 2000-08-11 2003-03-10 Метод за изменение на протеините на киназата с много на брой редове и изследване на съединенията, използвани за това

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63705400A 2000-08-11 2000-08-11
US09/637,054 2000-08-11

Publications (3)

Publication Number Publication Date
WO2002014536A2 WO2002014536A2 (fr) 2002-02-21
WO2002014536A3 true WO2002014536A3 (fr) 2003-01-30
WO2002014536A9 WO2002014536A9 (fr) 2003-12-18

Family

ID=24554347

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/024822 WO2002014536A2 (fr) 2000-08-11 2001-08-08 Procedes permettant de moduler des proteines kinase a lignee multiple et de cribler des composes les modulant

Country Status (19)

Country Link
EP (1) EP1309721A2 (fr)
JP (1) JP2005503102A (fr)
CN (1) CN1458979A (fr)
AU (2) AU8317901A (fr)
BG (1) BG107623A (fr)
BR (1) BR0113266A (fr)
CA (1) CA2419985A1 (fr)
CZ (1) CZ2003680A3 (fr)
HR (1) HRP20030162A2 (fr)
HU (1) HUP0501110A3 (fr)
IL (1) IL154311A0 (fr)
IS (1) IS6711A (fr)
MX (1) MXPA03001218A (fr)
NO (1) NO20030658L (fr)
NZ (1) NZ524034A (fr)
PL (1) PL366248A1 (fr)
SK (1) SK2692003A3 (fr)
WO (1) WO2002014536A2 (fr)
ZA (1) ZA200301109B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6811992B1 (en) 1998-05-14 2004-11-02 Ya Fang Liu Method for identifying MLK inhibitors for the treatment of neurological conditions
WO2005007144A2 (fr) * 2003-07-14 2005-01-27 Decode Genetics Ehf Methodes de diagnostic et de traitement de l'asthme et d'autres maladies respiratoires reposant sur une association d'haplotypes
US20060014165A1 (en) * 2003-07-14 2006-01-19 Decode Genetics Ehf. Methods of diagnosis and treatment for asthma and other respiratory diseases based on haplotype association
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
WO2014172616A2 (fr) * 2013-04-18 2014-10-23 President And Fellows Of Harvard College Méthodes, compositions et kits permettant de promouvoir la survie des neurones moteurs, de traiter et de diagnostiquer les maladies neurodégénératives
WO2018097628A2 (fr) * 2016-11-25 2018-05-31 주식회사 샤인바이오 Composition permettant de favoriser la différenciation de cellules souches neurales et de les protéger et procédé permettant d'induire une régénération neurale utilisant celle-ci

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
WO1999058982A1 (fr) * 1998-05-14 1999-11-18 Ya Fang Liu Procede d'identification de composes permettant d'empecher la mort cellulaire
WO2000013015A1 (fr) * 1998-08-26 2000-03-09 Cephalon, Inc. Modulation de proteines kinase a lignee multiple
WO2000047583A1 (fr) * 1999-02-12 2000-08-17 Cephalon, Inc. Pyrrolo-carbazoles et iso-indolones cycliques substitues condenses

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756494A (en) * 1992-07-24 1998-05-26 Cephalon, Inc. Protein kinase inhibitors for treatment of neurological disorders
US5705511A (en) * 1994-10-14 1998-01-06 Cephalon, Inc. Fused pyrrolocarbazoles
WO1999058982A1 (fr) * 1998-05-14 1999-11-18 Ya Fang Liu Procede d'identification de composes permettant d'empecher la mort cellulaire
WO2000013015A1 (fr) * 1998-08-26 2000-03-09 Cephalon, Inc. Modulation de proteines kinase a lignee multiple
WO2000047583A1 (fr) * 1999-02-12 2000-08-17 Cephalon, Inc. Pyrrolo-carbazoles et iso-indolones cycliques substitues condenses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FANGER G R ET AL: "MEKKs, GCKs, MLKs, PAKs, TAKs, and tpls: upstream regulators of the c-Jun amino-terminal kinases?", CURRENT OPINION IN GENETICS & DEVELOPMENT, CURRENT BIOLOGY LTD, XX, vol. 7, February 1997 (1997-02-01), pages 67 - 74, XP000867511, ISSN: 0959-437X *

Also Published As

Publication number Publication date
HUP0501110A2 (en) 2006-03-28
HUP0501110A3 (en) 2006-06-28
MXPA03001218A (es) 2003-05-27
BG107623A (bg) 2003-11-28
EP1309721A2 (fr) 2003-05-14
HRP20030162A2 (en) 2005-12-31
CA2419985A1 (fr) 2002-02-21
ZA200301109B (en) 2004-07-20
CN1458979A (zh) 2003-11-26
NZ524034A (en) 2006-11-30
JP2005503102A (ja) 2005-02-03
IS6711A (is) 2003-02-10
IL154311A0 (en) 2003-09-17
AU8317901A (en) 2002-02-25
BR0113266A (pt) 2005-01-04
NO20030658D0 (no) 2003-02-10
PL366248A1 (en) 2005-01-24
WO2002014536A9 (fr) 2003-12-18
WO2002014536A2 (fr) 2002-02-21
NO20030658L (no) 2003-04-09
AU2001283179B2 (en) 2006-07-13
CZ2003680A3 (cs) 2003-11-12
SK2692003A3 (en) 2003-08-05

Similar Documents

Publication Publication Date Title
WO2000013015A8 (fr) Modulation de proteines kinase a lignee multiple
WO2002099040A3 (fr) Ig utilises comme modificateurs de la voie p53 et methodes d'utilisation associees
WO2002099055A3 (fr) Cip comme modificateurs de la voie p53 et methodes d'utilisation associees
WO2005012241A3 (fr) Inhibiteurs de kinase p-38
WO1999036550A3 (fr) Molecules de proteases humaines
IL187254A (en) ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB
WO2004033666A3 (fr) Procedes et composes pour inhiber l'activite de hec1 dans le traitement des maladies proliferatives
WO2003066821A3 (fr) Molecules interagissant avec des polynucleotides et polypeptides casl (mical), et procedes d'utilisation associes
WO2002092013A3 (fr) Methodes de traitement des maladies du foie et des lesions du foie a l'aide de l'hormone de croissance et de la proteine foxm1b
WO2002014536A3 (fr) Procedes permettant de moduler des proteines kinase a lignee multiple et de cribler des composes les modulant
WO1999031128A3 (fr) Proteines du type facteur humain de necrose tumorale r2
WO1999038981A3 (fr) Molecules de proteine kinase humaines
WO1999041373A3 (fr) Molecules humaines associees au transport
EP1363528A4 (fr) Methodes de diagnostic et de traitement des cardiopathies
WO2003028536A3 (fr) Methodes permettant de diagnostiquer et de traiter les maladies cardiaques
WO2003023048A3 (fr) Methodes de diagnostic et de traitement de maladies et affections associees a la proteine kinase c$g(l)
WO2000078952A3 (fr) Proteines du metabolisme de l'arn
WO2003028537A3 (fr) Methodes de diagnostic et de traitement de maladies et d'etats pathologiques touchant le coeur ou le systeme digestif, ainsi que du cancer
WO2001041781A3 (fr) Inhibiteurs de proteine id pour le traitement de maladies oculaires
WO2003007800A3 (fr) Methodes pour diagnostiquer et traiter des maladies et des affections du systeme digestif et le cancer
WO2000061180A3 (fr) Produits et procedes destines au traitement de maladies associees a ptp lar
WO2004019880A3 (fr) Proteines interagissant avec aw755252 et leur utilisation
WO2001004305A3 (fr) Proteines humaines impliquees dans la detoxification
WO2003052070A3 (fr) Genes vps41 en tant que modificateurs de la mort cellulaire et procedes d'utilisation associe
AU2002363841A1 (en) Test system for identifying or testing active substances, which affect the growth and/or the survival of nerve cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 154311

Country of ref document: IL

Ref document number: 524034

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2419985

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2003/001218

Country of ref document: MX

Ref document number: 200301109

Country of ref document: ZA

Ref document number: 2002519661

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 018140017

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2001283179

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2692003

Country of ref document: SK

Ref document number: P20030162A

Country of ref document: HR

Ref document number: PV2003-680

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 10762301

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001961958

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001961958

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2003-680

Country of ref document: CZ

COP Corrected version of pamphlet

Free format text: SEQUENCE LISTING, 4 PAGES, ADDED